Type 2 diabetes is a leading cause of cardiovascular disease, blindness, renal failure and neurologic dysfunction in the United States. Current epidemiologic studies estimate that nearly 24 million Americans have type 2 diabetes and another 57 million have impaired glucose tolerance known as "pre-diabetes." On the whole, therapies for the treatment of type 2 diabetes receive widespread, restriction-free reimbursement on low formulary tiers because health plans understand the value of early and aggressive glycemic control. Nonetheless, patent expiry of several branded anti-diabetic therapies over the next three years, most-notably Takeda's Actos, will not only lead to in-class generic erosion, but will likely negatively impact reimbursement of all branded oral therapies and GLP-1 inhibitors.<\/p>\n
Using tiering and restrictions data from Fingertip Formulary, as well as insight from 44 pharmacy directors, this report determines the key trends in reimbursement of type 2 diabetes treatments, drivers of these trends, and how stakeholders can capitalize on future shifts in coverage to steal share from the competition.<\/p>\n","protected":false},"template":"","class_list":["post-116548","report","type-report","status-publish","hentry","report-gateway-marketaccess","marketaccess-state-alabama","marketaccess-state-alaska","marketaccess-state-arizona","marketaccess-state-arkansas","marketaccess-state-california","marketaccess-state-colorado","marketaccess-state-connecticut","marketaccess-state-delaware","marketaccess-state-district-of-columbia","marketaccess-state-florida","marketaccess-state-georgia","marketaccess-state-hawaii","marketaccess-state-idaho","marketaccess-state-illinois","marketaccess-state-indiana","marketaccess-state-iowa","marketaccess-state-kansas","marketaccess-state-kentucky","marketaccess-state-louisiana","marketaccess-state-maine","marketaccess-state-maryland","marketaccess-state-massachusetts","marketaccess-state-michigan","marketaccess-state-minnesota","marketaccess-state-mississippi","marketaccess-state-missouri","marketaccess-state-montana","marketaccess-state-nebraska","marketaccess-state-nevada","marketaccess-state-new-hampshire","marketaccess-state-new-jersey","marketaccess-state-new-mexico","marketaccess-state-new-york","marketaccess-state-north-carolina","marketaccess-state-north-dakota","marketaccess-state-ohio","marketaccess-state-oklahoma","marketaccess-state-oregon","marketaccess-state-pennsylvania","marketaccess-state-rhode-island","marketaccess-state-south-carolina","marketaccess-state-south-dakota","marketaccess-state-tennessee","marketaccess-state-texas","marketaccess-state-utah","marketaccess-state-vermont","marketaccess-state-virginia","marketaccess-state-washington","marketaccess-state-west-virginia","marketaccess-state-wisconsin","marketaccess-state-wyoming","marketaccess-date-566"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/116548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/116548\/revisions"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=116548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}